News
Gyrus Capital has held a final close on a €700 million single-asset continuation vehicle for Essential Pharma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback